Disease detection and treatment based on phenylacetylglutamine levels

• Main Authors: HAESEN SCOTT L, NEMETH ISHAN, SAHA PARTHA
• Format: Patent
• Language: Chinese; English
• Published: 30.12.2022
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PHYSICS; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; TESTING; VINEGAR; WINE

The present invention relates to systems, kits, and methods for identifying subjects having elevated levels of phenylacetylglutamine (PAG) or combinations of PAG and trimethylamine-n-oxide (TMAO) and/or N6-trimethyl-lysine (TML) and/or PSA and/or betaine and/or choline, as well as determining a disease (e.g., a disease-related disease) based on such levels. CVD, heart failure, asthma, diabetes, thrombosis, and lethal prostate cancer. In certain embodiments, the subject is free of chronic kidney disease and/or has type II diabetes. In particular embodiments, a subject is treated with a therapeutic agent, such as a beta-adrenergic blocker, an alpha2 adrenergic receptor agonist, an alpha2 adrenergic receptor antagonist, an antibiotic or a mixture of antibiotics, or a prostate cancer therapeutic agent. In certain embodiments, a subject is treated with a procedure such as brachytherapy, radiation therapy, or prostatectomy. 本发明涉及用于鉴定具有升高的苯乙酰谷氨酰胺(PAG)或PAG和三甲胺-n-氧化物(TMAO)和/或N6-三甲基-赖氨酸(TML)和/或PSA和/或甜菜碱和/或胆碱的组合的水平的受试者的